Back to Search Start Over

Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States

Authors :
Eric Adjei Boakye
Nosayaba Osazuwa-Peters
Julia López
Vy T. Pham
Betelihem B. Tobo
Leping Wan
Mario Schootman
Jane A. McElroy
Source :
Human Vaccines & Immunotherapeutics, Vol 17, Iss 2, Pp 428-433 (2021)
Publication Year :
2021
Publisher :
Taylor & Francis Group, 2021.

Abstract

Objectives We compared HPV vaccine initiation and completion of heterosexual with lesbian and bisexual (LB) women. Methods We aggregated National Health and Nutrition Examination Survey data from 2009 to 2016 for 3,017 women aged 18 to 34 y in the United States. HPV vaccine initiation was defined as reported receipt of ≥1 dose of the vaccine and completion as receipt of the three recommended doses. Weighted percentages and multivariable logistic regression models were used to examine differences in HPV vaccine initiation and completion between heterosexual and LB women. Results Approximately 12% of respondents self-identified as LB women. Overall, a higher percentage of respondents (26%) had initiated the HPV vaccine than completed the three vaccine doses (17%). In the bivariate analysis, LB women had higher initiation ([35% of LB women versus 25% heterosexual]; p = .0012) and completion rates ([24% of LB women versus 17% heterosexual]; p = .0052) than heterosexual women. After adjusting for covariates, compared to heterosexual women, LB women were 60% (aOR = 1.60, 95% CI: 1.16–2.19) more likely to initiate and 63% (aOR = 1.63, 95% CI: 1.12–2.37) more likely to complete the HPV vaccine. Conclusions Although LB women had higher likelihood of HPV vaccine initiation and completion compared with heterosexual women, their HPV vaccine uptake was well below the Healthy People 2020 target (80%). Understanding differences in the drivers of vaccine uptake in the LB population may inform strategies that would further increase HPV vaccine uptake toward achieving the 80% completion target.

Details

Language :
English
ISSN :
21645515 and 2164554X
Volume :
17
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Human Vaccines & Immunotherapeutics
Publication Type :
Academic Journal
Accession number :
edsdoj.47d7a8d20584c7995a4208ec19e1760
Document Type :
article
Full Text :
https://doi.org/10.1080/21645515.2020.1778407